-78%

est. 2Y upside i

HealthcareSeed

Spun out from FutureHouse in 2025, Edison Scientific accelerates discovery and innovation across the sciences. Our platform empowers researchers to move from question to breakthrough faster than ever, automating literature synthesis, data analysis, and molecular design

Rank

#1108

Sector

Drug Discovery

Est. Liquidity

~5Y

Data Quality

Data: Medium

Edison Scientific presents a moderate upside opportunity, driven by its strong competitive moat and impressive AI platform in a rapidly growing market.

Last updated: March 10, 2026

Bull (30%)+300%

Edison's Kosmos platform achieves widespread adoption among major pharmaceutical and materials science enterprises, demonstrating consistent 6-month-in-one-day research acceleration and 80% reproducibility. This leads to significant revenue growth, strategic partnerships, and a successful Series B/C round, pushing valuation to $1B+ within two years, establishing Edison as a market leader in autonomous AI for scientific discovery.

Base (35%)+50%

Edison continues to gain traction with academic and power users, securing initial enterprise clients and proving its value proposition. While facing intensifying competition from incumbents and other startups, it maintains a strong product roadmap and raises a successful Series A/B round, growing its valuation to approximately $375M, reflecting steady progress and market validation.

Bear (35%)-75%

Edison faces significant challenges in scaling commercial adoption, with longer-than-expected sales cycles and strong competitive pressure from well-funded incumbents like Google DeepMind and Anthropic, or other 'AI for science' startups. This leads to slower growth, difficulty in raising subsequent funding at a higher valuation, or a down round, potentially reducing the valuation to $62.5M and significantly impacting common stock value due to liquidation preferences.

Est. time to liquidity~5.0 years

Preference Stack Risk

high

Funding Intensity

28%

Investors hold $70M in liquidation preferences ahead of common stock, meaning in an exit at or below $250M, common shareholders would only see value above the $70M preference.

Dilution Risk

high

As a seed-stage company, Edison will require multiple future funding rounds, each leading to further dilution for early equity holders.

Secondary Liquidity

none

At this early stage, there are no active secondary markets or tender offers for Edison Scientific equity.

Questions to Ask at the Interview

Strategic questions based on Edison's data — designed to show you've done your homework.

  • 1

    “Given the strong claims about Kosmos's efficiency (6 months of research in one day) and 80% reproducibility, how is Edison planning to scale its commercial adoption beyond early academic and power users to large enterprise clients, particularly in the highly regulated pharmaceutical industry?”

  • 2

    “With major players like Google DeepMind and Anthropic actively pursuing scientific discovery, and other well-funded startups like Periodic Labs and Lila Sciences in the 'AI for science' niche, what are Edison's key strategies to maintain and expand its competitive moat over the next 2-3 years?”

  • 3

    “Considering the $70M seed funding at a $250M valuation, how does Edison envision its future funding rounds and potential liquidity events, and what mechanisms are in place to ensure meaningful returns for common stock holders amidst potential dilution and liquidation preferences?”

Community

Valuation Sentiment

Our model estimates -78% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.